Press Releases – NASDAQ (US) Website

Press Releases

Apr 19, 2022
BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series    read more...
Apr 15, 2022
China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma    read more...
Apr 11, 2022
IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia    read more...
Apr 08, 2022
BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors at the AACR Annual Meeting 2022    read more...
Apr 06, 2022
BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Applications for Tislelizumab for the Treatment of Patients with ESCC and NSCLC    read more...
Mar 15, 2022
BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia    read more...
Mar 11, 2022
China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors    read more...
Mar 03, 2022
BeiGene Announces Health Canada Approval for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Marginal Zone Lymphoma    read more...
Mar 01, 2022
BeiGene to Present at the Cowen 42nd Annual Health Care Virtual Conference    read more...
Feb 25, 2022
BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results    read more...
Feb 22, 2022
BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia    read more...
Feb 22, 2022
BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma    read more...
Feb 17, 2022
BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström’s Macroglobulinemia    read more...
Feb 08, 2022
BeiGene to Present at the Guggenheim Healthcare Talks - 2022 Oncology Conference    read more...
Feb 01, 2022
Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors    read more...
Jan 28, 2022
BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation    read more...
Jan 24, 2022
BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction Cancer    read more...
Jan 20, 2022
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenström’s Macroglobulinemia    read more...
Jan 06, 2022
BeiGene to Present at the J.P. Morgan 40th Annual Healthcare Conference    read more...
Jan 06, 2022
China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer    read more...